{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methotrexate-Sulfasalazine-Hydroxychloroquine",
    "query": {
      "intervention": "Methotrexate-Sulfasalazine-Hydroxychloroquine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methotrexate-Sulfasalazine-Hydroxychloroquine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T23:52:27.522Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01709578",
      "title": "To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "leflunomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 546,
      "start_date": "2012-10",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 56,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709578"
    },
    {
      "nct_id": "NCT02873936",
      "title": "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match filgotinib",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 449,
      "start_date": "2016-07-27",
      "completion_date": "2018-06-26",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 55,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873936"
    },
    {
      "nct_id": "NCT02374021",
      "title": "Treatments Against RA and Effect on FDG-PET/CT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2016-07",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2022-10-26",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374021"
    },
    {
      "nct_id": "NCT00259610",
      "title": "Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 755,
      "start_date": "2004-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-07-17",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00259610"
    },
    {
      "nct_id": "NCT02057250",
      "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RA"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Auto-Injector Device (AID)",
          "type": "DEVICE"
        },
        {
          "name": "Pre-filled Syringe (PFS)",
          "type": "DEVICE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2014-03",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 31,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057250"
    },
    {
      "nct_id": "NCT01313208",
      "title": "Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "DMARD Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 210,
      "start_date": "2011-03",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313208"
    },
    {
      "nct_id": "NCT00579878",
      "title": "Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate-Sulfasalazine-Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide-Sulfasalazine-Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 69,
      "start_date": "2001-03-27",
      "completion_date": "2010-03-11",
      "has_results": true,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579878"
    },
    {
      "nct_id": "NCT07138898",
      "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatic Disease"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anakinra",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ixekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bimekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guselkumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Risankizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-12-12",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07138898"
    },
    {
      "nct_id": "NCT00720798",
      "title": "An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Disease-modifying anti-rheumatic drugs",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal anti-inflammatory drugs",
          "type": "DRUG"
        },
        {
          "name": "Oral corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2067,
      "start_date": "2005-09",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 138,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720798"
    },
    {
      "nct_id": "NCT03414502",
      "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2007-12-10",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-28T23:52:27.522Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414502"
    }
  ]
}